BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 25130168)

  • 1. Enriched CD44(+)/CD24(-) population drives the aggressive phenotypes presented in triple-negative breast cancer (TNBC).
    Ma F; Li H; Wang H; Shi X; Fan Y; Ding X; Lin C; Zhan Q; Qian H; Xu B
    Cancer Lett; 2014 Oct; 353(2):153-9. PubMed ID: 25130168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome.
    Idowu MO; Kmieciak M; Dumur C; Burton RS; Grimes MM; Powers CN; Manjili MH
    Hum Pathol; 2012 Mar; 43(3):364-73. PubMed ID: 21835433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Features of CD44+/CD24-low phenotypic cell distribution in relation to predictive markers and molecular subtypes of invasive ductal carcinoma of the breast.
    Gudadze M; Kankava Q; Mariamidze A; Burkadze G
    Georgian Med News; 2014 Mar; (228):81-7. PubMed ID: 24743129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype.
    Ricardo S; Vieira AF; Gerhard R; Leitão D; Pinto R; Cameselle-Teijeiro JF; Milanezi F; Schmitt F; Paredes J
    J Clin Pathol; 2011 Nov; 64(11):937-46. PubMed ID: 21680574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Semi-quantitative evaluation of CD44(+) /CD24(-) tumor cell distribution in breast cancer tissue using a newly developed fluorescence immunohistochemical staining method.
    Kai M; Onishi H; Souzaki M; Tanaka H; Kubo M; Tanaka M; Katano M
    Cancer Sci; 2011 Dec; 102(12):2132-8. PubMed ID: 21838786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distribution of CD44/CD24 positive cells in ductal invasive carcinoma of breast of different grade and molecular subtype.
    Gudadze M; Kankava K; Mariamidze A; Mosidze T; Burkadze G
    Georgian Med News; 2013 Sep; (222):50-7. PubMed ID: 24099815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of CD44+CD24- cells on non-sentinel axillary lymph node metastases in sentinel node-positive breast cancer.
    Nogi H; Suzuki M; Kamio M; Kato K; Kawase K; Toriumi Y; Takeyama H; Fukushima H; Morikawa T; Uchida K
    Oncol Rep; 2011 Apr; 25(4):1109-15. PubMed ID: 21308353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic regulation of cancer stem cell genes in triple-negative breast cancer.
    Kagara N; Huynh KT; Kuo C; Okano H; Sim MS; Elashoff D; Chong K; Giuliano AE; Hoon DS
    Am J Pathol; 2012 Jul; 181(1):257-67. PubMed ID: 22626806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinicopathological and prognostic significance of CD24, CD44, CD133, ALDH1 expressions in invasive ductal carcinoma of the breast: CD44/CD24 expression in breast cancer.
    Kapucuoğlu N; Bozkurt KK; Başpınar Ş; Koçer M; Eroğlu HE; Akdeniz R; Akçil M
    Pathol Res Pract; 2015 Oct; 211(10):740-7. PubMed ID: 26298632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of cancer stem cell markers in basal and penta-negative breast carcinomas--a study of a series of triple-negative tumors.
    Uchôa Dde M; Graudenz MS; Callegari-Jacques SM; Hartmann CR; Ferreira BP; Fitarelli-Kiehl M; Edelweiss MI
    Pathol Res Pract; 2014 Jul; 210(7):432-9. PubMed ID: 24726267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD44(+)/CD24(-) cells are transit progenitors and do not determine the molecular subtypes and clinical parameters in breast carcinomas.
    Lü X; Xu K; Lü H; Yin Y; Ma C; Liu Y; Li H; Suo Z
    Ultrastruct Pathol; 2011 Apr; 35(2):72-8. PubMed ID: 21299347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer stem cells markers CD44, CD24 and ALDH1 in breast cancer special histological types.
    de Beça FF; Caetano P; Gerhard R; Alvarenga CA; Gomes M; Paredes J; Schmitt F
    J Clin Pathol; 2013 Mar; 66(3):187-91. PubMed ID: 23112116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical detection of breast cancer stem cells in hormone receptor-positive breast cancer and their role in response to endocrine therapy and clinical outcome.
    Hashimoto K; Shimizu C; Tsuda H; Saji S; Osaki A; Shigekawa T; Aogi K
    Oncology; 2012; 82(3):168-74. PubMed ID: 22433454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical implications of Ezrin and CD44 co‑expression in breast cancer.
    Ma L; Jiang T
    Oncol Rep; 2013 Oct; 30(4):1899-905. PubMed ID: 23900701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinicopathological significance of CD44+/CD24-/low and CD24+ tumor cells in invasive micropapillary carcinoma of the breast.
    Li W; Liu F; Lei T; Xu X; Liu B; Cui L; Wei J; Guo X; Lang R; Fan Y; Gu F; Tang P; Zhang X; Fu L
    Pathol Res Pract; 2010 Dec; 206(12):828-34. PubMed ID: 20977976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolation and characterization of tumorigenic extrahepatic cholangiocarcinoma cells with stem cell-like properties.
    Wang M; Xiao J; Shen M; Yahong Y; Tian R; Zhu F; Jiang J; Du Z; Hu J; Liu W; Qin R
    Int J Cancer; 2011 Jan; 128(1):72-81. PubMed ID: 20232394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells.
    Reim F; Dombrowski Y; Ritter C; Buttmann M; Häusler S; Ossadnik M; Krockenberger M; Beier D; Beier CP; Dietl J; Becker JC; Hönig A; Wischhusen J
    Cancer Res; 2009 Oct; 69(20):8058-66. PubMed ID: 19826050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between epidermal growth factor receptor and tumor stem cell markers CD44/CD24 and their relationship with prognosis in breast invasive ductal carcinoma.
    Zheng Z; Shao N; Weng H; Li W; Zhang J; Zhang L; Yang L; Ye S
    Med Oncol; 2015 Jan; 32(1):275. PubMed ID: 25429827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD44(high)CD24(low) molecular signature determines the Cancer Stem Cell and EMT phenotype in Oral Squamous Cell Carcinoma.
    Ghuwalewala S; Ghatak D; Das P; Dey S; Sarkar S; Alam N; Panda CK; Roychoudhury S
    Stem Cell Res; 2016 Mar; 16(2):405-17. PubMed ID: 26926234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer.
    Ring A; Kaur P; Lang JE
    BMC Cancer; 2020 Nov; 20(1):1076. PubMed ID: 33167919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.